MYRBETRIQ
Total Payments
$6.9M
Transactions
227,161
Doctors
46,904
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.1M | 61,140 | 22,154 |
| 2020 | $900,825 | 32,676 | 15,602 |
| 2019 | $2.8M | 71,766 | 24,843 |
| 2018 | $2.2M | 61,559 | 22,619 |
| 2017 | $5,819 | 20 | 18 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3.8M | 224,933 | 55.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 685 | 25.7% |
| Unspecified | $569,964 | 321 | 8.2% |
| Consulting Fee | $453,209 | 71 | 6.6% |
| Travel and Lodging | $220,808 | 632 | 3.2% |
| Space rental or facility fees (teaching hospital only) | $81,200 | 53 | 1.2% |
| Education | $2,442 | 466 | 0.0% |
Payments by Type
General
$6.3M
226,840 transactions
Research
$569,964
321 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A STUDY OF MIRABEGRON AND PELVIC FLOOR REHABILITATION FOR OVERACTIVE BLADDER IN MULTIPLE SCLEROSIS. | Astellas Pharma Global Development | $72,352 | 0 |
| Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity | Astellas Pharma Global Development | $68,303 | 0 |
| A Study of Mirabegron for Overactive Bladder in patients with Parkinson Disease PD and Cognitive Impairment CI | Astellas Pharma Global Development | $60,728 | 0 |
| A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH | Astellas Pharma Global Development | $50,680 | 4 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder OAB Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH | Astellas Pharma Global Development | $40,124 | 3 |
| PolyAch: Insights from the AUA Quality Registry | Astellas Pharma Global Development | $36,950 | 0 |
| An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity NDO on Clean Intermittent Catheterization CIC | Astellas Pharma Global Development | $31,846 | 0 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center, Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder OAB | Astellas Pharma Global Development | $30,845 | 4 |
| Mirabegron for Erectile Dysfunction | Astellas Pharma Global Development | $23,822 | 0 |
| MYRBETRIQ MIRABEGRON TO REDUCE PAIN AND DISCOMFORT FOLLOWING URETERAL STENT PLACEMENT | Astellas Pharma Global Development | $21,788 | 0 |
| Mirabegron in Achalasia A Clinical and Manometric Proof of Concept Pilot Study | Astellas Pharma Global Development | $20,850 | 0 |
| Mirabegron for Erectile Dysfunction | Astellas US Technologies | $20,801 | 0 |
| A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease | Astellas Pharma Global Development | $20,450 | 0 |
| A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder OAB | Astellas Pharma Global Development | $16,830 | 1 |
| MIRABEGRON IN ACHALASIA: A CLINICAL AND MANOMETRIC PROOF OF CONCEPT PILOT STUDY | Astellas Pharma Global Development | $10,678 | 0 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) | Astellas Pharma Global Development | $8,552 | 3 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder OAB | Astellas Pharma Global Development | $6,662 | 3 |
| A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER, STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN OLDER ADULT SUBJECTS WITH OVERACTIVE BLADDER OAB | Astellas Pharma Global Development | $3,326 | 0 |
| An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | Astellas Pharma Global Development | $3,250 | 0 |
| Real world evidence of treatment with mirabegron and antimuscarinics use among frail overactive bladder patients in the US | Astellas Pharma Global Development | $3,134 | 1 |
Top Doctors Receiving Payments for MYRBETRIQ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $535,492 | 218 |
| , MD | Urology | Brighton, MA | $142,159 | 180 |
| , MD | Urology | Greensboro, NC | $120,501 | 140 |
| , MD | Cardiovascular Disease | Owings Mills, MD | $94,800 | 2 |
| , MD | Urology | San Antonio, TX | $93,957 | 77 |
| , D.O | Family Medicine | Winchester, KS | $83,064 | 155 |
| , M.D | Public Health & General Preventive Medicine | Roxbury, MA | $54,675 | 1 |
| , M.D | Urology | Putnam, CT | $49,222 | 43 |
| , MD | Cardiovascular Disease | Boston, MA | $47,550 | 2 |
| , M.D | Urology | Ann Arbor, MI | $46,331 | 55 |
| , M.D | Pediatric Hematology-Oncology | Boston, MA | $45,900 | 3 |
| , M.D | Specialist | Norwalk, CT | $42,709 | 47 |
| , MD | Urology | Columbus, OH | $42,629 | 51 |
| , M.D | Urology | Webster, TX | $41,905 | 57 |
| , MD | Urology | Corona, CA | $41,413 | 47 |
| , MD | Urology | Greenbelt, MD | $39,171 | 41 |
| , M.D | Family Medicine | Jackson, MI | $38,226 | 41 |
| , MD | Urology | West Bloomfield, MI | $33,604 | 77 |
| , M.D | Urology | Lubbock, TX | $33,259 | 55 |
| , MD | Urology | Cleveland, OH | $33,124 | 56 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Charlotte, NC | $32,562 | 26 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Stroudsburg, PA | $30,779 | 32 |
| , MD | Specialist | Burien, WA | $29,577 | 44 |
| , MD | Urology | Bluffton, SC | $28,765 | 45 |
| , MD | Pediatric Urology | Jamaica Plain, MA | $28,240 | 12 |
Ad
Manufacturing Companies
- Astellas Pharma US Inc $5.9M
- Astellas Pharma Global Development $944,181
- Astellas Pharma Europe BV $41,901
- Astellas US Technologies $20,801
- Astellas Pharma Inc $16,849
Product Information
- Type Drug
- Total Payments $6.9M
- Total Doctors 46,904
- Transactions 227,161
About MYRBETRIQ
MYRBETRIQ is a drug associated with $6.9M in payments to 46,904 healthcare providers, recorded across 227,161 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma US Inc.
Payment data is available from 2017 to 2021. In 2021, $1.1M was paid across 61,140 transactions to 22,154 doctors.
The most common payment nature for MYRBETRIQ is "Food and Beverage" ($3.8M, 55.1% of total).
MYRBETRIQ is associated with 20 research studies, including "A STUDY OF MIRABEGRON AND PELVIC FLOOR REHABILITATION FOR OVERACTIVE BLADDER IN MULTIPLE SCLEROSIS." ($72,352).